These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25515780)

  • 1. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
    Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    Nissen SE; Wolski K
    N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
    Nissen SE; Wolski K
    Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
    Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical issues regarding rosiglitazone meta-analysis.
    Claggett B; Wei LJ
    Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rosiglitazone: no increase in cardiovascular mortality].
    Jazet IM; Meinders AE
    Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
    Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
    JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
    Lincoff AM; Wolski K; Nicholls SJ; Nissen SE
    JAMA; 2007 Sep; 298(10):1180-8. PubMed ID: 17848652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
    Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
    BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
    Mahaffey KW; Hafley G; Dickerson S; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Lopes RD
    Am Heart J; 2013 Aug; 166(2):240-249.e1. PubMed ID: 23895806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
    Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
    J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.